Dinesh Khanna

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. pmc Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound
    Elena Schiopu
    Division of Rheumatology Department of Internal Medicine, University of Michigan Scleroderma Program, Suite 7C27, 300 North Ingalls Street, SPC 5422, Ann Arbor, MI 48109, USA
    Rheumatology (Oxford) 53:704-13. 2014
  2. pmc Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinic
    Dinesh Khanna
    Division of Rheumatology, University of Michigan, Ann Arbor, MI 48106, USA
    Value Health 15:128-34. 2012
  3. pmc A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease
    Dinesh Khanna
    David Geffen School of Medicine, University of California, Los Angeles, USA
    Arthritis Rheum 63:3540-6. 2011
  4. pmc Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, University of Michigan, 24 Frank Lloyd Wright Drive, Lobby M, Suite 2500, SPC 5753, Ann Arbor, MI 48106, USA
    J Rheumatol 38:1920-4. 2011
  5. pmc Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group
    Dinesh Khanna
    University of California, Los Angeles, CA, USA
    Arthritis Rheum 63:3078-85. 2011
  6. pmc Minimally important differences of the gout impact scale in a randomized controlled trial
    Dinesh Khanna
    Department of Medicine, Division of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, University of California at San Diego, La Jolla, CA 90095, USA
    Rheumatology (Oxford) 50:1331-6. 2011
  7. ncbi request reprint Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials
    Karen Au
    Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Curr Rheumatol Rep 11:111-9. 2009
  8. pmc Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study
    Dinesh Khanna
    Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 48:1537-40. 2009
  9. pmc Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort
    Veena K Ranganath
    UCLA, Department of Medicine, Division of Rheumatology, Rehabilitation Center, Room 32 59, 1000 Veteran Avenue, Los Angeles, CA 90095 1670, USA
    Ann Rheum Dis 66:1633-40. 2007
  10. pmc Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study
    Jonathan Goldin
    Department of Radiologic Sciences, David Geffen School of Medicine, School of Public Health, University of California Los Angeles, Los Angeles, CA 90095, USA
    Chest 136:1333-40. 2009

Detail Information

Publications82

  1. pmc Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound
    Elena Schiopu
    Division of Rheumatology Department of Internal Medicine, University of Michigan Scleroderma Program, Suite 7C27, 300 North Ingalls Street, SPC 5422, Ann Arbor, MI 48109, USA
    Rheumatology (Oxford) 53:704-13. 2014
    ..SSc is associated with an increased prevalence of atherosclerosis (ATS). This study assessed the prevalence of subclinical ATS as measured by carotid US and explored serum proteins to identify potential biomarkers of SSc-ATS...
  2. pmc Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinic
    Dinesh Khanna
    Division of Rheumatology, University of Michigan, Ann Arbor, MI 48106, USA
    Value Health 15:128-34. 2012
    ..We hypothesized that the PROMIS item banks can be administered in a clinical setting if there is adequate staff support without disrupting the flow of clinic...
  3. pmc A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease
    Dinesh Khanna
    David Geffen School of Medicine, University of California, Los Angeles, USA
    Arthritis Rheum 63:3540-6. 2011
    ..In this 1-year, phase I/IIa open-label pilot study of imatinib in patients with SSc-related active ILD, our primary aim was to assess the safety of imatinib; we also explored its efficacy...
  4. pmc Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, University of Michigan, 24 Frank Lloyd Wright Drive, Lobby M, Suite 2500, SPC 5753, Ann Arbor, MI 48106, USA
    J Rheumatol 38:1920-4. 2011
    ..To provide minimally important difference (MID) estimates for the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 (UCLA SCTC GIT 2.0) in a longitudinal observational cohort...
  5. pmc Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group
    Dinesh Khanna
    University of California, Los Angeles, CA, USA
    Arthritis Rheum 63:3078-85. 2011
    ..The aim of this study was to assess the natural history of the decline in FVC% predicted in patients receiving placebo in the Scleroderma Lung Study and to evaluate possible factors for cohort enrichment in future therapeutic trials...
  6. pmc Minimally important differences of the gout impact scale in a randomized controlled trial
    Dinesh Khanna
    Department of Medicine, Division of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, University of California at San Diego, La Jolla, CA 90095, USA
    Rheumatology (Oxford) 50:1331-6. 2011
    ..Our objective was to assess minimally important differences (MIDs) for the GIS administered in a randomized controlled trial (RCT) assessing rilonacept vs placebo for prevention of gout flares during initiation of allopurinol therapy...
  7. ncbi request reprint Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials
    Karen Au
    Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Curr Rheumatol Rep 11:111-9. 2009
    ..A randomized double-blind controlled trial by the Scleroderma Lung Study Research Group is currently comparing the efficacy and safety of mycophenolate mofetil versus oral cyclophosphamide...
  8. pmc Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study
    Dinesh Khanna
    Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 48:1537-40. 2009
    ..Our objective was to assess minimally important difference (MID) for Mahler's Transition Dyspnoea Index (TDI) in SLS...
  9. pmc Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort
    Veena K Ranganath
    UCLA, Department of Medicine, Division of Rheumatology, Rehabilitation Center, Room 32 59, 1000 Veteran Avenue, Los Angeles, CA 90095 1670, USA
    Ann Rheum Dis 66:1633-40. 2007
    ....
  10. pmc Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study
    Jonathan Goldin
    Department of Radiologic Sciences, David Geffen School of Medicine, School of Public Health, University of California Los Angeles, Los Angeles, CA 90095, USA
    Chest 136:1333-40. 2009
    ..This study examined thoracic high-resolution CT (HRCT) scans obtained during the SLS for treatment-associated changes over time...
  11. ncbi request reprint Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Clin Exp Rheumatol 28:S55-62. 2010
    ..Recent investigations into the pathogenesis of SSc-ILD have led to a renewed interest in assessing targeted therapies in SSc-ILD. With this in mind, we propose recommendations for the design of future SSc-ILD studies in this review...
  12. pmc Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study
    Tracy Frech
    Department of Internal Medicine, Division of Rheumatology, University of Utah, Salt Lake City, UT, USA
    Rheumatology (Oxford) 50:1280-7. 2011
    ..Rheumatologic disorders are associated with sleep disturbances. This study examines sleep disturbance correlates in patients with SSc...
  13. pmc Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease
    Michael D Roth
    Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095 1690, USA
    Arthritis Rheum 63:2797-808. 2011
    ..To identify baseline characteristics of patients with scleroderma-related interstitial lung disease (SSc-ILD) that could serve as predictors of the most favorable response to 12-month treatment with oral cyclophosphamide (CYC)...
  14. pmc Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials
    Sogol Amjadi
    Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Arthritis Rheum 60:2490-8. 2009
    ....
  15. pmc Valuation of scleroderma and psoriatic arthritis health states by the general public
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    Health Qual Life Outcomes 8:112. 2010
    ..Our objective was to assess health values (utilities) from the general public for health states common to people with PsA and SSc for economic evaluations...
  16. pmc Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
    Dinesh Khanna
    University of California, Los Angeles, CA, USA
    Arthritis Rheum 61:1257-63. 2009
    ..To refine the previously developed scleroderma (systemic sclerosis [SSc]) gastrointestinal tract (GIT) instrument (SSC-GIT 1.0)...
  17. doi request reprint Adverse events during the Scleroderma Lung Study
    Daniel E Furst
    David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90025, USA
    Am J Med 124:459-67. 2011
    ..We now report an in-depth assessment of the toxicity of cyclophosphamide during the year of therapy and the year after therapy was completed, during which time the investigators were still masked to the treatment assignment...
  18. pmc Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis
    Veena K Ranganath
    University of California at Los Angeles, 1000 Veteran Avenue, Rehab Building 32 59, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 52:1809-17. 2013
    ....
  19. pmc Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis
    Anagha A Divekar
    Division of Rheumatology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA 90095, USA
    Clin Immunol 141:293-303. 2011
    ..Thus, imatinib might confer its therapeutic effect in fibrosis via re-directing T cell responses from type 2 to other, non-type 2 cytokine producing CD4(+) T cells...
  20. pmc Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials
    Mahsa Nashid
    Department of Medicine, David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 50:335-42. 2011
    ....
  21. pmc Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials
    Marian Kaldas
    UCLA Olive View, Sylmar, CA, USA
    Rheumatology (Oxford) 48:1143-6. 2009
    ..Our objective was to evaluate the sensitivity of change over time of individual body sites used in the calculation of total MRSS...
  22. pmc Validating and assessing the sensitivity of the Health Assessment Questionnaire-Disability Index-derived Short Form-6D in patients with early aggressive rheumatoid arthritis
    Sogol S Amjadi
    Division of Rheumatology, University of California Los Angeles School of Medicine, Department of Health Services, 1000 Veteran Avenue, Room 32 59, Rehabilitation Center, Los Angeles, CA 90095, USA
    J Rheumatol 36:1150-7. 2009
    ..We evaluated the construct validity of the HAQ-DI-derived Short Form-6D (SF-6D) score and assessed its responsiveness to change over 6- and 12-month followup periods in patients with early aggressive rheumatoid arthritis (RA)...
  23. pmc Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial
    Dinesh Khanna
    David Geffen School of Medicine, and School of Public Health, University of California, Los Angeles, USA
    Arthritis Rheum 60:1102-11. 2009
    ....
  24. pmc Combination of echocardiographic and pulmonary function test measures improves sensitivity for diagnosis of systemic sclerosis-associated pulmonary arterial hypertension: analysis of 2 cohorts
    Heather Gladue
    From the University of Michigan Scleroderma Program Division of Rheumatology, Department of Medicine, Georgetown University, Washington, DC, USA Department of Rheumatology A, Paris Descartes University, Cochin Hospital, Assistance Publique Hopitaux de Paris, Paris, France St Joseph s Hospital and Medical Center, Division of Pulmonary, Department of Medicine, Phoenix, AZ David Geffen School of Medicine at UCLA, Division of Pulmonary, Department of Medicine, Los Angeles, CA Arizona State University, Biodesign Institute, Tempe, AZ Department of Biostatistics, University of Michigan, School of Public Health, Ann Arbor, MI, USA and Paris XIII University, Cardiology Department, Avicenne Hospital, Bobigny, France
    J Rheumatol 40:1706-11. 2013
    ....
  25. doi request reprint Development of an online library of patient-reported outcome measures in gastroenterology: the GI-PRO database
    Puja Khanna
    Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA
    Am J Gastroenterol 109:234-48. 2014
    ..It is important to develop a mechanism for identifying, categorizing, and evaluating the over 100 GI PROs that exist. Here we describe a new, National Institutes of Health (NIH)-supported, online PRO clearinghouse-the GI-PRO database...
  26. pmc Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey
    Puja P Khanna
    University of Michigan, MI, USA
    Health Qual Life Outcomes 10:117. 2012
    ..The present study quantifies the impact of the presence of tophi and frequency of acute gout attacks on health-related quality of life (HRQOL), productivity, and healthcare resource utilization...
  27. ncbi request reprint Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort
    Dinesh Khanna
    Division of Immunology, Department of Medicine, University of Cincinnati and the Veterans Affairs Medical Center, Cincinnati, Ohio 45267 0563, USA
    Arthritis Rheum 57:440-7. 2007
    ..To evaluate published proposed definitions of minimal disease activity (MDA) and remission in patients with early rheumatoid arthritis (RA)...
  28. pmc Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis
    Vijay Bodukam
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 50:330-4. 2011
    ..0 instrument; and (ii) to explore which GI-specific symptom scales are associated with depressed mood in patients with SSc...
  29. pmc Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry
    Sangmee Bae
    Department of Internal Medicine, University of California, Los Angeles, California, USA
    Ann Rheum Dis 71:1335-42. 2012
    ..The objectives of this analysis were to examine the baseline characteristics in systemic sclerosis (SSc) with normal and borderline mPAP and to explore long-term outcomes in SSc patients with borderline mPAP versus normal haemodynamics...
  30. pmc IRF5 polymorphism predicts prognosis in patients with systemic sclerosis
    Roozbeh Sharif
    Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Ann Rheum Dis 71:1197-202. 2012
    ..The goal of this study was to investigate the impact of these gene variants on survival and severity of interstitial lung disease (ILD) in SSc...
  31. pmc Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout
    Puja P Khanna
    Department of Medicine, David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 50:740-5. 2011
    ..Short Form-36 (SF-36) is a validated outcome measure to assess health-related quality of life (HRQOL) in patients with gout. We assessed responsiveness to change of SF-36 in patients with gout...
  32. pmc Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study
    Karen Au
    University of California, Los Angeles, Los Angeles, CA 90025, USA
    Arthritis Care Res (Hoboken) 62:1772-8. 2010
    ..Subjects were then followed off the study agent for an additional 12 months...
  33. pmc Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study
    Tien I Karleen Su
    University of Southern California, Los Angeles, CA 90095 1670, USA
    Arthritis Rheum 60:3821-30. 2009
    ..To assess the safety and efficacy of rapamycin in the treatment of diffuse systemic sclerosis (SSc; scleroderma)...
  34. ncbi request reprint Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)
    Dinesh Khanna
    David Geffen School at University of California, Los Angeles, CA, USA
    J Rheumatol 36:2356-61. 2009
    ..CRISS and EPOSS are being developed through the OMERACT process. Through Delphi process and literature review significant progress has been made for both indices, and prospective data are being collected...
  35. ncbi request reprint Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
    Sangmee Bae
    David Geffen School of Medicine, UCLA, Los Angeles, USA
    Clin Exp Rheumatol 29:S15-21. 2011
    ..Our objective was to translate the UCLA-GIT 2.0 from English to French and to evaluate the reliability and validity of the French version...
  36. pmc Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database
    Veena K Ranganath
    Department of Medicine, Division of Rheumatology, UCLA Rehabilitation Center, University of California, Los Angeles, California 90095 1670, USA
    J Rheumatol 35:1966-71. 2008
    ....
  37. ncbi request reprint Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis
    Sangmee Bae
    University of California Medical Center, Los Angeles, USA
    Clin Exp Rheumatol 31:57-63. 2013
    ..The objective of our study was to assess the associations between the upper GI (UGI) symptom scales (reflux and distention/bloating [D/B] scales) versus objective/laboratory studies...
  38. doi request reprint Oral cyclophosphamide for active scleroderma lung disease: a decision analysis
    Dinesh Khanna
    Division of Rheumatology, School of Public Health, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Med Decis Making 28:926-37. 2008
    ..Also, the long-term balance of risk and benefit remains unclear...
  39. doi request reprint The disutility of chronic gout
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, 1000 Veteran Avenue, Los Angeles, CA 90095, USA
    Qual Life Res 17:815-22. 2008
    ..Gout is a chronic painful inflammatory arthritis. Data regarding the impact of gout on health-related quality of life, however, are limited...
  40. pmc Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial
    Puja P Khanna
    Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 49:955-9. 2010
    ....
  41. ncbi request reprint Predictors of doctor-rated and patient-rated gout severity: gout impact scales improve assessment
    Andrew J Sarkin
    Health Services Research Center, University of California, San Diego, California, USA
    J Eval Clin Pract 16:1244-7. 2010
    ..Our objective was to describe the factors associated with doctor-rated and patient-rated gout severity to explain how doctor assessment involving patient-reported outcomes can improve the clinical management of gout...
  42. pmc Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension
    Dinesh Khanna
    University of Michigan, Ann Arbor
    Arthritis Rheum 65:3194-201. 2013
    ..Therefore, we sought to develop recommendations for screening and early detection of CTD-associated PAH...
  43. pmc Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease
    Donald P Tashkin
    Department of Medicine, David Geffen School of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1690, USA
    Am J Respir Crit Care Med 176:1026-34. 2007
    ..Although treatment-related benefits in pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1 year of therapy, the duration of benefit beyond 1 year was unclear...
  44. ncbi request reprint Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study
    Dinesh Khanna
    David Geffen School of Medicine, University of California, Los Angeles, USA
    Arthritis Rheum 52:592-600. 2005
    ....
  45. doi request reprint Understanding gastrointestinal distress: a framework for clinical practice
    Brennan M R Spiegel
    Department of Gastroenterology, VA Greater Los Angeles Healthcare System, Los Angeles, California, USA
    Am J Gastroenterol 106:380-5. 2011
    ..When appropriate, screen for suicidal ideations. Finally, we provide a list of high-yield questions to screen for these maladaptive cognitions and emotions, and explain how the GI distress framework can be used in clinical practice...
  46. doi request reprint Patterns of radiographic outcomes in early, seropositive rheumatoid arthritis: a baseline analysis
    Grace S Park
    Amgen Inc, Thousand Oaks, CA, USA
    Contemp Clin Trials 32:160-8. 2011
    ..The identified clusters and rates may correspond better with clinical status and treatment over the disease course than linear progression rates alone...
  47. ncbi request reprint Stress activation of cellular markers of inflammation in rheumatoid arthritis: protective effects of tumor necrosis factor alpha antagonists
    Sarosh J Motivala
    UCLA Semel Institute for Neuroscience and Human Behavior, Cousins Center for Psychoneuroimmunology, University of California, Los Angeles 90095 7076, USA
    Arthritis Rheum 58:376-83. 2008
    ..The purpose of this study was to determine whether RA patients show increased monocyte production of TNFalpha following acute psychological stress and whether such responses are abrogated in RA patients taking TNFalpha antagonists...
  48. ncbi request reprint High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease
    Jonathan G Goldin
    David Geffen School of Medicine at UCLA, Department of Radiology, Los Angeles, CA 90095 1721, USA
    Chest 134:358-67. 2008
    ..The frequency, nature, and progression of interstitial lung disease seen on high-resolution CT (HRCT) scans in patients with diffuse SSc (dcSSc) compared with those with limited SSc (lcSSc) has not been well characterized...
  49. ncbi request reprint Evaluation of an instrument assessing influence of Gout on health-related quality of life
    Jan D Hirsch
    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093 0714, USA
    J Rheumatol 35:2406-14. 2008
    ..To evaluate the reliability and validity of an instrument assessing the influence of gout (acute and chronic) on health-related quality of life (HRQOL)...
  50. pmc The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    J Rheumatol 35:2339-43. 2008
    ..To estimate the minimally important difference (MID) for a fatigue visual analog scale (VAS) using patient-reported anchors (fatigue, pain, and overall health)...
  51. ncbi request reprint Classifying radiographic progression status in early rheumatoid arthritis patients using propensity scores to adjust for baseline differences
    Grace S Park
    Department of Biostatistics, School of Public Health, University of California, Los Angeles, CA 90095 1772, USA
    Stat Methods Med Res 16:13-29. 2007
    ..05) nonprogression in patients given earlier treatment. We conclude that propensity score analysis reduced but did not remove all bias...
  52. ncbi request reprint Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria
    Sindhu R Johnson
    Division of Rheumatology, Department of Medicine, Toronto Western Hospital, University of Toronto, Ground Floor, East Wing, 399 Bathurst Street, Toronto, Ontario, Canada M5T 2S8 Division of Rheumatology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada Electronic address
    J Clin Epidemiol 67:706-14. 2014
    ....
  53. pmc Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis
    Karen Au
    University of California, Los Angeles, CA, USA
    Arthritis Rheum 63:2078-90. 2011
    ..The aim of this study was to perform a systematic review and meta-analysis to determine whether the risk of atherosclerosis is increased in SSc patients compared to healthy individuals...
  54. ncbi request reprint Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study
    Christina Charles-Schoeman
    Division of Rheumatology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, California 90095 1670, USA
    J Rheumatol 34:1459-64. 2007
    ..We examined the effects of atorvastatin 80 mg daily on the inflammatory properties of HDL and clinical disease activity in RA...
  55. doi request reprint The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials
    Janet E Pope
    Division of Rheumatology, Department of Medicine, University of Western Ontario, London, Canada
    J Rheumatol 36:254-9. 2009
    ....
  56. pmc Evidence-based management of rapidly progressing systemic sclerosis
    Dinesh Khanna
    UCLA Scleroderma Program, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Best Pract Res Clin Rheumatol 24:387-400. 2010
    ..Some of the recent clinical trials are reviewed and discussed in detail...
  57. doi request reprint Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities
    Rajeev Saggar
    David Geffen School of Medicine at University of California, Los Angeles, CA 90095 1690, USA
    Arthritis Rheum 62:3741-50. 2010
    ..We undertook this study to describe the hemodynamic response to exercise in a homogeneous population of patients with scleroderma spectrum disorders at risk of developing pulmonary vascular disease...
  58. pmc Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study
    Daniel E Furst
    Division of Rheumatology, Department of Medicine, University of California Los Angeles, CA 90095 1670, USA
    Ann Rheum Dis 66:893-9. 2007
    ..To incorporate a new trial design to examine clinical response, cytokine expression and joint imaging in patients with rheumatoid arthritis (RA) switching from etanercept to infliximab treatment...
  59. pmc Measuring response in the gastrointestinal tract in systemic sclerosis
    Dinesh Khanna
    aUniversity of Michigan, Ann Arbor, Michigan bCedars Sinai Medical Center, Los Angeles, California cUniversity of Utah, Salt Lake City, Utah, USA
    Curr Opin Rheumatol 25:700-6. 2013
    ..Gastrointestinal tract (GIT) involvement in systemic sclerosis (scleroderma, SSc) is the most common internal complication. This review discusses the outcome measures to capture GIT involvement in clinical care and trials...
  60. ncbi request reprint Outcome measures in acute gout: a systematic literature review
    Nicola Dalbeth
    From the Department of Medicine, University of Auckland, Auckland Department of Medicine, University of Otago, Wellington, New Zealand Division of Rheumatology, University of Michigan, Ann Arbor, Michigan and Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA
    J Rheumatol 41:558-68. 2014
    ..We evaluated instruments for these domains according to the OMERACT filter: truth, feasibility, and discrimination...
  61. doi request reprint Arthritis in systemic sclerosis: systematic review of the literature and suggestions for the performance of future clinical trials in systemic sclerosis arthritis
    Philip J Clements
    David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1670, USA
    Semin Arthritis Rheum 41:801-14. 2012
    ....
  62. pmc Health-related quality of life in adults reporting arthritis: analysis from the National Health Measurement Study
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, 1000 Veteran Avenue, Rm 32 59 Rehabilitation Building, Los Angeles, CA 90095, USA
    Qual Life Res 20:1131-40. 2011
    ..Arthritis is the leading cause of disability in the United States. We assess the generic health-related quality-of-life (HRQOL) among a nationally representative sample of U.S. adults with and without self-reported arthritis...
  63. ncbi request reprint Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trial
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    J Rheumatol 35:466-8. 2008
    ..We assessed if HAQ-DI scores are different when calculated with and without aids/devices, and if apparent responsiveness changes when scored in these 2 ways...
  64. pmc Quality indicator set for systemic sclerosis
    Dinesh Khanna
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA
    Clin Exp Rheumatol 29:S33-9. 2011
    ..Our objective was to develop QIs for patients with SSc...
  65. ncbi request reprint Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention
    Tracy M Frech
    Division of Rheumatology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA
    Clin Exp Rheumatol 29:S22-5. 2011
    ..Our hypothesis is that GIT symptoms in SSc patients with moderate bloating would improve with probiotic implementation...
  66. pmc A randomized study of scleroderma health state values: a picture is worth a thousand words, and quite a few utiles. [corrected]
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Med Decis Making 29:7-14. 2009
    ..We assess utilities from the general public for health states common in scleroderma (SSc) by describing the health states in writing alone v. with photographs of patients with SSc...
  67. ncbi request reprint Validation of single-factor structure and scoring protocol for the Health Assessment Questionnaire-Disability Index
    Jason C Cole
    University of California, Los Angeles, CA, USA
    Arthritis Rheum 53:536-42. 2005
    ..However, HAQ-DI scoring has not been validated. The purpose of this study was to examine the structural validity of the HAQ-DI and evaluate the latent factors underlying HAQ-DI scoring...
  68. ncbi request reprint Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, Los Angeles, California, USA
    J Rheumatol 32:832-40. 2005
    ....
  69. ncbi request reprint Outcome evaluations in gout
    H Ralph Schumacher
    Division of Rheumatology, University of Pennsylvania School of Medicine, and Veterans Affairs Medical Center, Philadelphia, Pennsylvania 19104, USA
    J Rheumatol 34:1381-5. 2007
    ..Final validation of these outcomes has not yet been achieved. In summary, the unique problems of evaluating outcomes in gout are finally being addressed. While no measures are available for use yet, an agenda has been developed...
  70. pmc Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials
    Heather Gladue
    University of Michigan Scleroderma Program, Ann Arbor, MI 48109, USA
    Arthritis Care Res (Hoboken) 65:630-6. 2013
    ....
  71. pmc Development of a provisional core set of response measures for clinical trials of systemic sclerosis
    D Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, California 90095, USA
    Ann Rheum Dis 67:703-9. 2008
    ..To develop a provisional core set of response measures for clinical trials of systemic sclerosis (SSc)...
  72. ncbi request reprint The impact of rheumatoid arthritis and treatment on patients' lives
    Vibeke Strand
    Division of Immunology Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA
    Clin Exp Rheumatol 28:S32-40. 2010
    ..These extend the more traditional measures of efficacy into outcomes that are more central to patients' daily lives...
  73. pmc Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: a population-based study
    Tracy Frech
    University of Utah, Division of Rheumatology, Department of Medicine, Salt Lake City, UT 84132, USA
    Arthritis Rheum 62:2109-16. 2010
    ..To investigate the familiality of systemic sclerosis (SSc) in relation to Raynaud's phenomenon (RP) (a marker of vasculopathy), other autoimmune inflammatory disease, and fibrotic interstitial lung disease (ILD)...
  74. doi request reprint Use of a medication control officer to reduce bias in a clinical trial: lessons learned from the scleroderma lung study
    Vivien M Hsu
    Division of Rheumatology, UMDNJ Scleroderma Program, New Brunswick, NJ 08903, USA
    Clin Trials 7:85-9. 2010
    ....
  75. pmc Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Ophthalmology 117:133-139.e2. 2010
    ..To study the effectiveness of anti-CD20 (rituximab [RTX]; Rituxan; Genentech, Inc., South San Francisco, CA) therapy in patients with severe, corticosteroid (CS)-resistant thyroid-associated ophthalmopathy (TAO)...
  76. doi request reprint Developing disease activity and response criteria in connective tissue disease-related interstitial lung disease
    Lesley Ann Saketkoo
    Section of Rheumatology, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    J Rheumatol 38:1514-8. 2011
    ..We summarize the design of the studies we are conducting and progress leading to the OMERACT 10 and 2010 EULAR meetings...
  77. pmc The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial
    Puja P Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Ann Rheum Dis 69:588-91. 2010
    ..The Raynaud's condition score (RCS) is a validated outcome measure for Raynaud's phenomenon (RP)...
  78. ncbi request reprint Systemic sclerosis - continuing progress in developing clinical measures of response
    Daniel Furst
    University of California at Los Angeles, Los Angeles, California 90025, USA
    J Rheumatol 34:1194-200. 2007
    ..Another Delphi exercise is designed to develop consensus regarding a combined SSc response index to be validated in future RCT...
  79. ncbi request reprint Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies
    Dinesh Khanna
    Division of Immunology, Department of Medicine, University of Cincinnati and Veterans Affairs Medical Center, Cincinnati, Ohio 45267 0563, USA
    Arthritis Rheum 52:3030-8. 2005
    ..To examine the effect of folic acid on the efficacy of methotrexate (MTX) treatment in rheumatoid arthritis (RA) at 12 months in 2 phase III randomized controlled trials (RCTs) of leflunomide in which MTX was used as a comparator...
  80. ncbi request reprint Health-related quality of life--an introduction
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, 1000 Veterans Ave, Rm 32 59 Rehabilitation Bldg, Los Angeles, CA 90095, USA
    Am J Manag Care 13:S218-23. 2007
    ....
  81. ncbi request reprint Meloxicam in rheumatoid arthritis
    Mansoor Ahmed
    David Geffen School of Medicine, Los Angeles, CA, USA
    Expert Opin Drug Metab Toxicol 1:739-51. 2005
    ..Clinical trials have shown that meloxicam at 7.5 - 15 mg/day is as effective as diclofenac, piroxicam and naproxen as an anti-inflammatory and analgesic, and was associated with fewer GI adverse effects...
  82. ncbi request reprint Association of tumor necrosis factor alpha polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort
    Dinesh Khanna
    David Geffen School of Medicine at the University of California, Los Angeles, and the Veterans Affairs Medical Center, Cincinnati, Ohio 45267 0563, USA
    Arthritis Rheum 54:1105-16. 2006
    ..To determine whether the tumor necrosis factor alpha (TNFA) -308 guanine-to-adenosine polymorphism and/or the shared epitope (SE) is associated with radiographic damage in patients with early rheumatoid arthritis (RA)...